Gastrointestinal stromal tumors

Margaret Von Mehren; James C. Watson

doi:10.1016/j.hoc.2005.03.010

Gastrointestinal stromal tumors

Margaret Von Mehren, James C. Watson

Fox Chase Cancer Center

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Gastrointestinal stromal tumors (GISTs) are identified pathologically by the expression of KIT. The management of GISTs has been altered significantly by the development of imatinib mesylate, a tyrosine kinase inhibitor with activity against KIT and platelet-derived growth factor receptors. This article reviews the management of GISTs in the era of molecular therapies. The role of surgery alone or in combination with imatinib in the adjuvant and metastatic setting is discussed. GISTs resistant to imatinib are becoming a clinical challenge; this article discusses novel therapies under development.

Original language	English
Pages (from-to)	547-564
Number of pages	18
Journal	Hematology/Oncology Clinics of North America
Volume	19
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2005.03.010
State	Published - Jun 2005

Keywords

Antineoplastic Agents/therapeutic use
Benzamides
Drug Resistance, Neoplasm
Gastrointestinal Stromal Tumors/drug therapy
Humans
Imatinib Mesylate
Piperazines/therapeutic use
Proto-Oncogene Proteins c-kit/metabolism
Pyrimidines/therapeutic use

Access to Document

10.1016/j.hoc.2005.03.010

Cite this

@article{a3ce19c2323f4ec9b7bb1de4e156d2f0,

title = "Gastrointestinal stromal tumors",

abstract = "Gastrointestinal stromal tumors (GISTs) are identified pathologically by the expression of KIT. The management of GISTs has been altered significantly by the development of imatinib mesylate, a tyrosine kinase inhibitor with activity against KIT and platelet-derived growth factor receptors. This article reviews the management of GISTs in the era of molecular therapies. The role of surgery alone or in combination with imatinib in the adjuvant and metastatic setting is discussed. GISTs resistant to imatinib are becoming a clinical challenge; this article discusses novel therapies under development.",

keywords = "Antineoplastic Agents/therapeutic use, Benzamides, Drug Resistance, Neoplasm, Gastrointestinal Stromal Tumors/drug therapy, Humans, Imatinib Mesylate, Piperazines/therapeutic use, Proto-Oncogene Proteins c-kit/metabolism, Pyrimidines/therapeutic use",

author = "{Von Mehren}, Margaret and Watson, {James C.}",

year = "2005",

month = jun,

doi = "10.1016/j.hoc.2005.03.010",

language = "English",

volume = "19",

pages = "547--564",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Gastrointestinal stromal tumors

AU - Von Mehren, Margaret

AU - Watson, James C.

PY - 2005/6

Y1 - 2005/6

N2 - Gastrointestinal stromal tumors (GISTs) are identified pathologically by the expression of KIT. The management of GISTs has been altered significantly by the development of imatinib mesylate, a tyrosine kinase inhibitor with activity against KIT and platelet-derived growth factor receptors. This article reviews the management of GISTs in the era of molecular therapies. The role of surgery alone or in combination with imatinib in the adjuvant and metastatic setting is discussed. GISTs resistant to imatinib are becoming a clinical challenge; this article discusses novel therapies under development.

AB - Gastrointestinal stromal tumors (GISTs) are identified pathologically by the expression of KIT. The management of GISTs has been altered significantly by the development of imatinib mesylate, a tyrosine kinase inhibitor with activity against KIT and platelet-derived growth factor receptors. This article reviews the management of GISTs in the era of molecular therapies. The role of surgery alone or in combination with imatinib in the adjuvant and metastatic setting is discussed. GISTs resistant to imatinib are becoming a clinical challenge; this article discusses novel therapies under development.

KW - Antineoplastic Agents/therapeutic use

KW - Benzamides

KW - Drug Resistance, Neoplasm

KW - Gastrointestinal Stromal Tumors/drug therapy

KW - Humans

KW - Imatinib Mesylate

KW - Piperazines/therapeutic use

KW - Proto-Oncogene Proteins c-kit/metabolism

KW - Pyrimidines/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=20444385887&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2005.03.010

DO - 10.1016/j.hoc.2005.03.010

M3 - Review article

C2 - 15939196

AN - SCOPUS:20444385887

SN - 0889-8588

VL - 19

SP - 547

EP - 564

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Gastrointestinal stromal tumors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this